A review of sleep disturbance in hepatitis C

Journal of Clinical Gastroenterology

Volumn 44, Issue 1, 2010, Pages 38-45

  Sockalingam, Sanjeev ^a,b   Abbey, Susan E ^a,b   Alosaimi, Fahad ^a,b,c   Novak, Marta ^a,b,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

^d SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Hepatitis C; Liver diseases; Sleep

Indexed keywords

ALPHA INTERFERON; ANTIHISTAMINIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; ESZOPICLONE; HYDROXYZINE; INTERFERON; LEVODOPA; LORAZEPAM; MELATONIN; MIRTAZAPINE; MODAFINIL; OLANZAPINE; OXAZEPAM; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PRAMIPEXOLE; QUETIAPINE; RAMELTEON; RIBAVIRIN; RISPERIDONE; TEMAZEPAM; TRAZODONE; TRIAZOLAM; TRYPTOPHAN; UNINDEXED DRUG; ZALEPLON; ZOLPIDEM; ZOPICLONE;

ADD ON THERAPY; AMNESIA; ANTEROGRADE AMNESIA; BEDTIME DOSAGE; CIRCADIAN RHYTHM SLEEP DISORDER; COGNITIVE THERAPY; DAYTIME SOMNOLENCE; DELIRIUM; DEPRESSION; DISEASE CLASSIFICATION; DIZZINESS; DROWSINESS; DRUG ABSORPTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; EVENING DOSAGE; FATIGUE; HEPATIC ENCEPHALOPATHY; HEPATITIS C; HUMAN; HYPERSOMNIA; IMMUNOTHERAPY; INFORMATION RETRIEVAL; INSOMNIA; IRRITABILITY; LIVER TOXICITY; MENTAL DISEASE; MOOD DISORDER; NEUTROPENIA; NONHUMAN; PARASOMNIA; PATHOPHYSIOLOGY; POLYSOMNOGRAPHY; PRIORITY JOURNAL; PRURITUS; PSYCHOMOTOR DISORDER; PSYCHOSIS; RESTLESS LEGS SYNDROME; RETROGRADE AMNESIA; REVIEW; RISK FACTOR; SCREENING TEST; SEDATION; SEROTONIN METABOLISM; SIDE EFFECT; SLEEP APNEA SYNDROME; SLEEP DISORDER; SLEEP DISORDERED BREATHING; SOMNOLENCE; SUICIDAL IDEATION; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIVIRAL AGENTS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MENTAL DISORDERS; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; SLEEP DISORDERS;

EID: 75149158103     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCG.0b013e3181b314ea     Document Type: Review

References (91)

1. WHO. Hepatitis C: global prevalence. Wkly Epidemiol Rec. 1997;72:341-344.
2. Mucsi I, Molnar MZ, Ambrus C, et al. Restless legs syndrome, insomnia and quality of life in patients on maintenance dialysis. Nephrol Dial Transplant. 2005;20:571-577.
3. Kallman J, O'Neil MM, Larive B, et al. Fatigue and healthrelated quality of life (HQRL) in chronic hepatitis C virus infection. Dig Dis Sci. 2007;52:2531-2539.
4. Bini EJ, Brau N, Currie S, et al. Prospective multicenter study of eligibility for antiviral therapy among 4,084 US veterans with chronic hepatitis C virus infection. Am J Gastroenterol. 2005;100:1772-1779.
5. El-Sarag HB, Kunik M, Richardson P, et al. Psychiatric disorders among veterans with hepatitis C infection. Gastroenterology. 2002;123:476-482.
6. Raison CL, Demetrashvili M, Capuron L, et al. Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs. 2005;19:105-123.
7. American Academy of Sleep Medicine. International Classification of Sleep Disorders, 2nd ed, Diagnostic and Coding Manual. Westchester, IL: American Academy of Sleep Medicine. 2005.
8. National Institutes of Health, State-of-the-Science Conference Statement: Manifestations and Management of Chronic Insomnia in Adults. Available at http://consensus.nih.gov./ta/ 026/026InsomniaPostConfIntro.htm. 2005.
9. Lang CA, Conrad S, Garrett L, et al. Symptom prevalence and clustering of symptoms in people living with chronic hepatitis C infection. J Pain Symptom Manage. 2006;31:335-344.
10. Yovtcheva SP, Rifai MA, Moles JK, et al. Psychiatric comorbidity among hepatitis C-positive patients. Psychosomatics. 2001;42:411-415.
11. Carta MG, Hardoy MC, Garofalo A, et al. Association of chronic hepatitis C with major depressive disorders: irrespective of interferon-alpha therapy. Clin Pract Epidemol Ment Health. 2007;23:22.
12. Lee DH, Jamal H, Regenstein FG, et al. Morbidity of chronic hepatitis C as seen in a tertiary care medical center. Dig Dis Sci. 1997;42:186-191.
13. Butt AA, Khan UA, McGinnis KA, et al. Co-morbid medical and psychiatric illness and substance abuse in HCV-infected and uninfected veterans. J Viral Hepat. 2007;14:890-896.
14. Crespo J, Cifrian J, Pinto JA, et al. Sleep apnea obstructive syndrome: a new complication previously undescribed in cirrhotic patients with ascites. Am J Gastroenterol. 2003;98: 2815-2816.
15. Cordoba J, Cabrera J, Lataif L, et al. High prevalence of sleep disturbance in cirrhosis. Hepatology. 1998;27:339-345.
16. Morgenthaler T, Alessi C, Friedman L, et al. Practice parameters for the use of actigraphy in the assessment of sleep and sleep disorders: an update for 2007. Sleep. 2007;30: 519-529.
17. Franco RA, Ashwathnarayan R, Deshpandee A, et al. The high prevalence of restless legs syndrome symptoms in liver disease in an academic-based hepatology practice. J Clin Sleep Med. 2008;4:45-49.
18. Tembl JI, Ferrer JM, Sevilla MT, et al. Neurological complications associated with hepatitis C infection. Neurology. 1999;53:861-864.
19. Ogata T, Nomura M, Nakaya Y, et al. Evaluation of episodes of sleep apnea in patients with liver cirrhosis. J Med Invest. 2006;53:159-166.
20. Nikaina I, Pastaka C, Zachou K, et al. Sleep apnoea syndrome and early stage cirrhosis: a pilot study. Eur J Gastroenterol Hepatol. 2006;18:31-35.
21. Teodoro VV, Lucchesi L, Bragagnolo M, et al. Sleep aspects and sleepiness in patients with hepatitic cirrhosis. Sleep. 2008;31 (Abstract Supplement):A298.
22. Heathcote EJ, Shiffman ML, Cooksley GE, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med. 2000;343:1673-1680.
23. Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa- 2a in patients with chronic hepatitis C. N Engl J Med. 2000; 343:1666-1672.
24. Reddy KR, Wright TL, Pckros PJ, et al. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology. 2001;33:433-438.
25. Malaguarnera M, Laurino A, Di Fazio I, et al. Neuropsychiatric effects and type of IFN-alpha in chronic hepatitis C. J Inteferon Cytokine Res. 2001;21:273-278.
26. Neri S, Pulvirenti D, Bertino G. Psychiatric symptoms induced by antiviral therapy in chronic hepatitis C: comparison between interferon-alpha-2a and interferon-alpha-2b. Clin Drug Investig. 2006;26:655-662.
27. LaRochelle JS, Karp BI. Restless legs syndrome due to interferon-alpha. Mov Disord. 2004;19:730-731.
28. Horikawa N, Yamazaki T, Izumi N, et al. Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-alpha therapy: a prospective study. Gen Hosp Psych. 2003;25:34-38.
29. Bonaccorso S, Marino V, Biondi M, et al. Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus. J Affect Disord. 2002;72:237-241.
30. Wichers KC, Koek GH, Robaeys G, et al. Early increase in vegetative symptoms predicts IFN-alpha-induced cognitivedepressive changes. Psychol Med. 2005;35:433-441.
31. Gohier B, Goeb JL, Rannou-Dubas K, et al. Hepatitis C, alpha interferon, anxiety and depression disorders: a prospective study of 71 patients. World J Biol Psychiatry. 2003;4: 115-118.
32. Franzen PL, Buysse DJ, Rabinovitz M, et al. Poor sleep quality increases vulnerability for depression and irritability following interferon treatment (abstract). Sleep. 2008;31(Abstract Supplement): A36.
33. Constant A, Castera L, Dantzer R, et al. Mood alterations during interferon-alfa therapy in patients with chronic hepatitis C: evidence for an overlap between manic/hypomanic and depressive symptoms. J Clin Psychiatry. 2005;66: 1050-1057.
34. Bonaccorso S, Puzella A, Marino V, et al. Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms. Psychiatry Res. 2001;105:45-55.
35. Wichers MC, Kenis G, Leue C, et al. Baseline immune activation as a risk factor for the onset of depression during interferon-alpha treatment. Biol Psychiatry. 2006;60: 77-79.
36. Wichers MC, Kenis G, Koek GH, et al. Interferon-alphainduced depressive symptoms are related to changes in the cytokine network but not cortisol. J Psychosom Res. 2007; 62:207-214.
37. Kreuger JM, Majhde JA. Humoral links between sleep and the immune system: research issues. Ann N Y Acad Sci. 2003;992: 9-20.
38. Opp MR. Sleep and psychoneuroimmunology. Neurol Clin. 2006;24:493-506.
39. Okun ML, Giese S, Lin L, et al. Exploring the cytokine and endocrine involvement in narcolepsy. Brain Behav Immun. 2004;18:326-332.
40. Vgontzas AN, Papanicolaou DA, Bixler EO, et al. Circadian interleukin-6 secretion and quantity and depth of sleep. J Clin Endocrinol Metab. 1999;84:2603-2607.
41. Gerrard TL, Siegel JP, Dyer DR, et al. Differential effects of interferon-alpha and interferon-gamma on interleukin 1 secretion by monocytes. J Immunol. 1987;138:2535-2540.
42. Bonaccorso S, Marino V, Puzella A, et al. Increased depressive ratings in patients with hepatitis C receiving interferon-alphabased immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. J Clin Psychopharmocol. 2002;22:86-90.
43. Landolt HP, Kelsoe JR, Rapaport MH, et al. Rapid tryptophan depletion reverses phenelzine-induced suppression of REM sleep. J Sleep Res. 2003;12:13-18.
44. Moore P, Gillin C, Bhatti T, et al. Rapid tryptophan depletion, sleep electroencephalogram, and mood in men with remitted depression on serotonin reuptake inhibitors. Arch Gen Psychiatry. 1998;55:534-539.
45. Wichers MC, Koek GH, Robaeys G, et al. IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis tryptophan depletion to neurotoxicity. Mol Psychiatry. 2005;10:538-544.
46. Zignego AL, Cozzi A, Carpenedo R, et al. HCV patients, psychopathology and tryptophan metabolism: analysis of the effects of pegylated interferon plus ribavirin treatment. Dig Liver Dis. 2007;39(Suppl 1):S107-S111.
47. Waleh NS, Apte-Deshpande A, Terao A, et al. Modulation of the promotor region of prepro-hypocretin by alpha-interferon. Gene. 2001;262:123-128.
48. Wieczorek S, Dahmen N, Kasten M, et al. A rare form of narcolepsy (HLA-DR2-) shows possible association with (functionally relevant) alpha-interferon gene polymorphisms. Psychiatr Genet. 2004;14:47-51.
49. Kozanoglu E, Canataroglu A, Abayli B, et al. Fibromyalgia syndrome in patients with hepatitis C infection. Rheumatol Int. 2003;23:248-251.
50. Chen W, Wong T, Tomlinson G, et al. Prevalence and predictors of obesity among individuals with positive hepatitis C antibody in a tertiary referral clinic. J Hepatol. 2008; 49:711-717.
51. Buysse DJ, Reynolds CF, Monk TH, et al. The Pittsburgh Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28:193-213.
52. Soldatos CR, Dikeos DG, Paparrigopoulos TJ. The diagnostic validity of the Athens Insomnia Scale. J Psychosom Res. 2003;55:263-267.
53. Netzer NC, Stoohs RA, Netzer CM, et al. Using the Berlin Questionnaire to identify patients at risk for the sleep apnea syndrome. Ann Intern Med. 1999;131:485-491.
54. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991;14:540-545.
55. Walters AS, LeBrocq C, Dhar A, et al. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med. 2003;4: 121-132.
56. Allen R, Earley C. Validation of a diagnostic questionnaire for the restless legs syndrome (RLS) (abstract). Neurology. 2001; 58(8, suppl 3):A4.
57. Kushida CA, Littner MR, Morgenthaler T, et al. Practice parameters for the indications for polysomnography and related procedures: an update for 2005. Sleep. 2005;28: 499-521.
58. Schutte-Rodin S, Broch L, Buysse D, et al. Clinical guideline for the evaluation and management of chronic insomnia in adults. J Clin Sleep Med. 2008;4:487-504.
59. Littner MR, Kushida C, Wise M, et al. Practice parameters for clinical use of the multiple sleep latency test and the maintenance of wakefulness test. Sleep. 2005;28:113-121.
60. Chessen AL, Anderson WM, Littner M, et al. Practice parameters for the nonpharmacologic treatment of chronic insomnia. Sleep. 1999;22:1128-1133.
61. Morgenthaler T, Kramer M, Alessi C, et al. Practice parameters for the psychological and behavioral treatment of insomnia: an update. An American academy of sleep medicine report. Sleep. 2006;29:1415-1419.
62. Montgomery P, Dennis J. Cognitive behavioural interventions for sleep problems in adults aged 60+. Cochrane Database Syst Rev. 2003;1:CD003161.
63. Morin CM, Bootzin RR, Buysse DJ, et al. Psychological and behavioral treatment of insomnia: update of recent evidence (1998-2004). Sleep. 2006;29:1398-1414.
64. Morgan K, Dixon S, Mathers N, et al. Psychological treatment for insomnia in the regulation of long-term hypnotic drug use. Health Technol Assess. 2004;8:iii-iv, 1-64.
65. Dhillon S, Chung SA, Fargher T, et al. Sleep apnea, hypertension, and the effects of continuous positive airway pressure. Am J Hypertens. 2005;18:594-600.
66. Kawahara S, Akashiba T, Akahoshi T, et al. Nasal CPAP improves the quality of life and lessens the depressive symptoms in patients with obstructive sleep apnea syndrome. Intern Med. 2005;44:422-427.
67. Barbera J, Shapiro C. Benefit-risk assessment of zaleplon in the treatment of insomnia. Drug Saf. 2005;28:301-318.
68. Huet PM, Villeneuve JP. Determinants of drug disposition in patients with cirrhosis. Hepatology. 1983;3:913-918.
69. Maddock C, Baita A, Orru MG, et al. Psychopharmacological treatment of depression, anxiety, irritability and insomnia in patients receiving interferon-alpha: a prospective case series and a discussion of biological mechanisms. J Psychopharmacol. 2004;18:41-46.
70. Montplaisir J, Hawa R, Moller H, et al. Zopiclone and zaleplon versus benzodiazepines in the treatment of insomnia: Canadian consensus statement. Hum Psychopharmacol. 2003; 18:29-38.
71. Russo S, Boon JC, Korf J, et al. Mirtazapine for the treatment of interferon-induced pscyhopathology. Gen Hosp Psych. 2003; 25:497.
72. Schaefer M, Schwaiger M, Garkisch AS, et al. Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. J Hepatol. 2005;42:793-798.
73. Ozcanli T, Unsalver B, Ozdemir S, et al. Sertraline- and mirtazapine-induced severe neutropenia. Am J Psychiatry. 2005;162:1386.
74. Mendelson WB. A review of the evidence for the efficacy and safety of trazodone in insomnia. J Clin Psychiatry. 2005;66: 469-476.
75. Fernandes NF, MArtin RR, Schenker S. Trazodone-induced hepatotoxicity: a case report with comments on drug-induced hepatotoxicity. Am J Gastroenterol. 2000;95:532-535.
76. Rettman KS, McClintock C. Hepatotoxicity after short-term trazodone therapy. Ann Pharmacother. 2001;35:1559-1561.
77. Romero-Gomez M, Viloria MDM, Andrade RJ, et al. Insulin resistance impairs sustained response rate to perinterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology. 2005;128:636-641.
78. Bressler BL, Guindi M, Tomlinson G, et al. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology. 2003;38: 639-644.
79. Hosoda S, Takimura H, Shibayama M, et al. Psychiatric symptoms related to interferon therapy for chronic hepatitis C: clinical features and prognosis. Psychiatry Clin Neurosci. 2000; 54:565-572.
80. Onyike CU, Bonner JO, Lyketsos CG, et al. Mania during treatment of chronic hepatitis C with pegylated interferon and ribavirin. Am J Psychiatry. 2004;161:429-435.
81. Crone CC, Gabriel GM, DiMartini A. An overview of psychiatric issues in liver disease for the consultation-liaison psychiatrist. Psychosomatics. 2006;47:188-205.
82. Spahr L, Coeytaux A, Giostra E, et al. Histamine H1 blocker hydroxyzine improves sleep in patients with cirrhosis and minimal hepatic encephalopathy: a randomized controlled pilot trial. Am J Gastroenterol. 2007;102:744-753.
83. Schaefer M, Winterer J, Sarkar R, et al. Three cases of successful tryptophan add-on or monotherapy of hepatitis C and IFN-alpha-associated mood disorders. Psychosomatics. 2008;49:442-446.
84. Monti JM, Alvarino F, Cardinali C, et al. Polysomnographic study of the effect of melatonin on sleep in elderly patients with chornic primary insomnia. Arch Gerontol Geriatr. 1999; 28:85-98.
85. Haimov I. Melatonin rhythm abnormalities and sleep disorders in the elderly. CNS Spectr. 2001;6:502-506.
86. Zemlan FP, Mulchahey JJ, Scharf MB, et al. The efficacy and safety of the melatonin agonist beta-methyl-6-chloromelatonin in primary insomnia: a randomized, placebo-controlled, crossover clinical trial. J Clin Psychiatry. 2005;66:384-390.
87. Mathes AM, Kubulus D, Waibel L, et al. Selective activation of melatonin receptors with ramelteon improves liver function and hepatic perfusion after hemorrhagic shock in rat. Crit Care Med. 2008;36:2863-2870.
88. Zammit G, Erman M, Wang-Wigand S, et al. Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia. J Clin Sleep Med. 2007;3:495-504.
89. Martin KA, Krahn LE, Balan V, et al. Modafinil's use in combating interferon-induced fatigue. Dig Dis Sci. 2007;52: 893-896.
90. Silber MH, Ehrenberg BL, Allen RP, et al. An algorithm for the management of restless legs syndrome. Mayo Clin Proc. 2004;79:916-922.
91. Happe S, Sauter C, Klosch G, et al. Gabapentin versus ropinirole in the treatment of idiopathic restless legs syndrome. Neuropsychobiology. 2003;48:82-86.